ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

NERV Minerva Neurosciences Inc

2.4365
0.0065 (0.27%)
After Hours
Last Updated: 16:00:01
Delayed by 15 minutes

Period:

Draw Mode:

Volume 4,167
Bid Price 2.42
Ask Price 2.50
News -
Day High 2.49

Low
2.2864

52 Week Range

High
13.49

Day Low 2.43
Company Name Stock Ticker Symbol Market Type
Minerva Neurosciences Inc NERV NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0065 0.27% 2.4365 16:00:01
Open Price Low Price High Price Close Price Prev Close
2.45 2.43 2.49 2.4365 2.43
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
83 4,167 $ 2.45 $ 10,216 - 2.2864 - 13.49
Last Trade Time Type Quantity Stock Price Currency
19:39:14 10 $ 2.42 USD

Minerva Neurosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
17.06M 6.99M - 0 -30.01M -4.29 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Minerva Neurosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No NERV Message Board. Create One! See More Posts on NERV Message Board See More Message Board Posts

Historical NERV Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.502.592.432.507,142-0.0635-2.54%
1 Month2.582.802.28642.5117,246-0.1435-5.56%
3 Months8.5513.492.28644.50127,152-6.11-71.50%
6 Months4.5013.492.28644.8773,071-2.06-45.86%
1 Year2.3113.492.28648.87311,6100.12655.48%
3 Years2.4215.270.3278846.77878,0000.01650.68%
5 Years7.2915.270.3278845.88887,497-4.85-66.58%

Minerva Neurosciences Description

Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company focused on the development of product candidates to treat patients suffering from central nervous system diseases. Minerva is developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop MIN-301 for the treatment of Parkinson's disease. Minerva co-developed seltorexant with Janssen Pharmaceutica NV for the treatment of insomnia disorder and adjunctive treatment of Major Depressive Disorder.Minerva has not received any regulatory approvals to commercialize its product candidates and has not generated any revenue from the sales or license of any product candidates. Minerva has incurred significant operating losses since inception and expects to continue to incur net losses and negative cash flows from operating activities for the foreseeable future in connection with clinical and regulatory activities.

Your Recent History

Delayed Upgrade Clock